### Contents

**Highlights of This Issue** 509

**SPECIAL FEATURES**

**CCR Translations**

511  
Breast Cancer Stem Cells: We’ve Got Them Surrounded  
Hasan Korkaya and Max S. Wicha  
*See article, p. 643*

514  
A Focus on PD-L1 in Human Melanoma  
Peter Hersey and Stuart Gallagher  
*See article, p. 598*

**CCR New Strategies**

517  
New Strategies in Prostate Cancer: Translating Genomics into the Clinic  
Himisha Beltran and Mark A. Rubin  
*See article, p. 571*

**CCR Drug Updates**

524  
Vandetanib for the Treatment of Medullary Thyroid Cancer  
Nicole G. Chau and Robert I. Haddad

**Molecular Pathways**

530  
Molecular Pathways: Targeted α-Particle Radiation Therapy  
Kwamena E. Baaidoo, Kwon Yong, and Martin W. Brechbiel

**Perspective**

538  
Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer  
Margaret A. Tempero, David Klimstra, Jordan Berlin, Tony Hollingsworth, Paula Kim, Nipun Merchant, Malcolm Moore, Doug Pleskow, Andrea Wang-Gillam, and Andrew M. Lowy

**Review**

541  
Does Microenvironment Contribute to the Etiology of Estrogen Receptor–Negative Breast Cancer?  
Mary Helen Barcellos-Hoff

---

**HUMAN CANCER BIOLOGY**

549  
Deciphering the Mechanisms of Tumorigenesis in Human Pancreatic Ductal Epithelial Cells  
Zhe Chang, Zhongkui Li, Xiaoyang Wang, Ya’an Kang, Yuhui Yuan, Jianguo Niu, Huamin Wang, Deyali Chatterjee, Jason B. Fleming, Min Li, James L. Abbruzzese, and Paul J. Chiao

560  
SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival  
Mohamed Hassanein, Megan D. Hoeksema, Masakazu Shiotai, Jun Qian, Bradford K. Harris, Heidi Chen, Jonathan E. Clark, William E. Alborn, Rosana Eisenberg, and Pierre P. Massion

---

**CANCER THERAPY: PRECLINICAL**

586  
Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma  
Silvia Xargay-Torrent, Mónica López-Guerra, Arnau Montraveta, Ilgénia Saborit-Villarroya, Laia Rosich, Alba Navarro, Patricia Pérez-Galán, Gaël Roue, Elias Campo, and Dolors Colomer

598  
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition  
Xiaofeng Jiang, Jun Zhou, Anita Giobbie-Hurder, Jennifer Wargo, and F. Stephen Hodi  
*See commentary, p. 514*

610  
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function  
Joan T. Garrett, Cammie R. Sutton, María Gabriela Kuba, Rebecca S. Cook, and Carlos L. Arteaga
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>620</td>
<td>A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal</td>
<td>Giuseppe Floris, Agnieszka Wozniak, Raf Sciot, Hafiu Li, Lori Friedman, Thomas Van Looy, Jasmin Wellens, Peter Vermaelen, Christophe M. Deroose, Jonathan A. Fletcher, Maria Debiec-Rychter, and Patrick Schoffski</td>
</tr>
<tr>
<td>668</td>
<td>Systemic Administration of a Novel Immune-Stimulatory Pseudovirion Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN-γ Production</td>
<td>Kotaro Saga, Katsumi Tamai, Takehiko Yamazaki, and Yasufumi Kaneda</td>
</tr>
<tr>
<td>680</td>
<td>Antitumor Activity of Cell-Permeable RUNX3 Protein in Gastric Cancer Cells</td>
<td>Junghee Lim, Tam Dzoung, Nga Do, Phuoc Do, Jaetaek Kim, Hyuncheol Kim, Wael El-Rifai, H. Earl Ruley, and Daewoong Jo</td>
</tr>
<tr>
<td>691</td>
<td>Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing</td>
<td>Fiamma Buitilli, Lara Felicioni, Maela Del Gramastro, Giampaolo Filice, Alessia Di Lorio, Sara Malatesta, Patrizia Viola, Irene Centi, Tommaso D’Antuono, Roberta Zappacosta, Sandra Rosini, Franco Cuccurullo, and Antonio Marchetti</td>
</tr>
<tr>
<td>699</td>
<td>Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression</td>
<td>Éric Lévesque, Shu-Pin Huang, Étienne Audet-Walsh, Louis Lacombe, Bo-Ying Bao, Yves Fradet, Isabelle Laverdière, Mélanie Rouleau, Chao-Tyan Huang, Chia-Cheng Yu, Patrick Caron, and Chantal Guilleminette</td>
</tr>
<tr>
<td>710</td>
<td>Detection of miR-34a Promoter Methylation in Combination with Elevated Expression of c-Met and β-Catenin Predicts Distant Metastasis of Colon Cancer</td>
<td>Helge Siemers, Jens Neumann, Reinhard Jackstadt, Ulrich Mansmann, David Horst, Thomas Kirchner, and Heiko Heremeking</td>
</tr>
<tr>
<td>731</td>
<td>Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma</td>
<td>Kimberley Jones, Frank Varri, Colm Keane, Pauline Crooks, Jamie P. Nourse, Louise A. Seymour, David Gottlieb, David Ritchie, Devinder Gill, and Maher K. Gandhi</td>
</tr>
</tbody>
</table>
A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation
Anne-Marie C. Dingemans, Wouter W. Mellema, Harry J.M. Groen, Atie van Wijk, Sjaak A. Burgers, Peter W.A. Kunst, Erik Thunnissen, Danielle A.M. Heideman, and Egbert F. Smit

Correction: Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

ABOUT THE COVER

Cytology specimens may represent the only available material for molecular diagnosis in non–small cell lung cancer patients. When the number of neoplastic cells in these samples is very low in a large excess of nonneoplastic cells, the specimen is usually judged inadequate for mutation analysis with conventional methods. The cover figure shows a cytological smear obtained from a bronchoalveolar lavage with a limited number of tumor cells. Next-generation sequencing can greatly improve the detection of mutations in these cases. For details, see the article by Buttitta and colleagues on page 691 of this issue.